Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?-Reference-Cited by-同舟云学术

Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?

Published:2019-01-10 Issue:8 Volume:60 Page:2034-2041
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jain Tania¹,Kunze Katie L.²,Khetarpal Banveet K.³,McCallen Margaret R.⁴,Betcher Jeffrey A.⁴,Ofori Henry T.⁴,Khera Nandita¹,Slack James L.¹,Leis Jose F.¹,Sproat Lisa Z.¹,Noel Pierre¹,Palmer Jeanne¹

Affiliation:

1. Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix, AZ, USA;

2. Division of Biostatistics, Mayo Clinic, Phoenix, AZ, USA;

3. Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA;

4. Division of Pharmacy, Mayo Clinic, Phoenix, AZ, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1562183

Reference38 articles.

1. Busulfan in hematopoietic stem cell transplant setting

2. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality

3. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation

4. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

5. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS